1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Essential Thrombocythemia Disease Overview

3. Essential Thrombocythemia Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Essential Thrombocythemia Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Essential Thrombocythemia Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Essential Thrombocythemia companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Essential Thrombocythemia Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
COMPANIES
AAVogen Inc, Armgo Pharma Inc, Biophytis SA, Elevian Inc, Faraday Pharmaceuticals Inc , Immunoforge Ltd, Immusoft Corp, Keren Therapeutics, MYOS RENS Technology Inc, Neurotune AG, Novartis AG, Regeneron Pharmaceuticals Inc, Ridgeline Therapeutics LLC, Teijin Pharma Ltd

Companies mentioned
AbbVie Inc, Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Incyte Corp, MEI Pharma Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals, PharmaEssentia Corp, SELLAS Life Sciences Group Inc